DK108589A - Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer - Google Patents

Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer

Info

Publication number
DK108589A
DK108589A DK108589A DK108589A DK108589A DK 108589 A DK108589 A DK 108589A DK 108589 A DK108589 A DK 108589A DK 108589 A DK108589 A DK 108589A DK 108589 A DK108589 A DK 108589A
Authority
DK
Denmark
Prior art keywords
antibodies
chimerary
humant
dna sequences
sequences coding
Prior art date
Application number
DK108589A
Other languages
English (en)
Other versions
DK108589D0 (da
Inventor
Dennis J Carlo
Gary Samuel David
Mary Jaqueline Johnson
Catherine Brautigam Beidler
James Richard Ludwig
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of DK108589D0 publication Critical patent/DK108589D0/da
Publication of DK108589A publication Critical patent/DK108589A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK108589A 1988-03-09 1989-03-07 Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer DK108589A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16585688A 1988-03-09 1988-03-09
US27257788A 1988-11-17 1988-11-17

Publications (2)

Publication Number Publication Date
DK108589D0 DK108589D0 (da) 1989-03-07
DK108589A true DK108589A (da) 1989-09-22

Family

ID=26861757

Family Applications (1)

Application Number Title Priority Date Filing Date
DK108589A DK108589A (da) 1988-03-09 1989-03-07 Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer

Country Status (5)

Country Link
EP (1) EP0332424A3 (da)
JP (1) JPH029371A (da)
AU (1) AU618990B2 (da)
DK (1) DK108589A (da)
IL (1) IL89489A0 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5843708A (en) * 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
US5081235A (en) * 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
EP0457875A4 (en) * 1989-11-13 1993-03-03 Xoma Corporation Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
GB2276169A (en) * 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
CA2130436C (en) * 1992-02-19 2001-04-10 John S. Abrams Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6380979B1 (en) * 1996-07-02 2002-04-30 Matsushita Electric Industrial Co., Ltd. Scanning line converting circuit and interpolation coefficient generating circuit
CZ20014083A3 (cs) 1999-05-14 2002-08-14 Imclone Systems Incorporated Léčivo pro indikaci růstu refrakterních nádorů
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US6890532B2 (en) 2000-05-16 2005-05-10 Thomas Jefferson University Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
US7071319B2 (en) 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
KR101215701B1 (ko) 2002-07-19 2012-12-26 베스 이스라엘 데코니스 메디칼 센터 자간전증 또는 자간의 진단 및 치료 방법
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
CA2560305C (en) 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
ES2660341T3 (es) 2004-08-26 2018-03-21 The University Of Western Ontario Dianas bacterianas de adquisición de hierro
EP2347765B1 (en) 2004-09-24 2014-01-22 Beth Israel Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
CN101102791B (zh) 2004-11-18 2011-12-14 英克隆有限责任公司 抗血管内皮生长因子受体-1的抗体
WO2006083355A2 (en) 2004-11-19 2006-08-10 Cornell Research Foundation, Inc. Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
CA2612449A1 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
AU2006284922B2 (en) 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
MX338397B (es) 2007-08-29 2016-04-15 Sanofi Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US7951370B2 (en) 2008-03-12 2011-05-31 Imclone Llc Anti-TYRP1 antibodies
NZ591488A (en) 2008-09-07 2012-11-30 Glyconex Inc Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
EP2467492A4 (en) 2009-08-18 2013-01-09 Harvard College METHOD AND COMPOSITIONS FOR TREATING PROLIFERATIVE AND PATHOGENIC ILLNESSES
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
CN102812043A (zh) * 2009-11-19 2012-12-05 新加坡国立大学 用于制备t细胞受体样单克隆抗体的方法及其用途
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
EP2536432B1 (en) 2010-02-19 2018-08-08 Cornell University Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
EP3604339B1 (en) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
TW201628647A (zh) 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體
DE202014008375U1 (de) 2014-10-18 2015-10-21 Reinz-Dichtungs-Gmbh Seperatorplatte und elektrochemisches System
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
US20210230255A1 (en) 2018-04-27 2021-07-29 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
US11155638B2 (en) 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
JP7784898B2 (ja) 2019-05-24 2025-12-12 サノフイ 全身性硬化症を治療するための方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
IL89490A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Chimeric antibodies directed against metal chelates

Also Published As

Publication number Publication date
JPH029371A (ja) 1990-01-12
AU618990B2 (en) 1992-01-16
IL89489A0 (en) 1989-09-10
EP0332424A3 (en) 1991-07-03
AU3107289A (en) 1989-09-14
EP0332424A2 (en) 1989-09-13
DK108589D0 (da) 1989-03-07

Similar Documents

Publication Publication Date Title
DK108589A (da) Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer
DK108189A (da) Chimere antistoffer rettet mod humant carcinoembryonalt antigen og metal-chelater samt dna-sekvenser, der koder for saadanne antistoffer
DK296189A (da) Nucleinsyresekvenser, som koder for peptidsekvenser af carcinoembryonisk antigen-familien
DE68924227D1 (de) DNA-Fragment.
DE3879452D1 (de) Chimaere antikoerper.
NO891818L (no) T4-reseptor-protein, relaterte dna-sekvenser samt fremstilling derav.
DE68907519D1 (de) Biosensoren.
NO892612D0 (no) Gruspakningssystem.
DE3887130D1 (de) Ferro-elektrisches Festhalteverfahren.
FI962247L (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
DE68922772D1 (de) Verfahren zur Zeichenkettenermittlung.
DK38989A (da) Dna-sekvens
DE68914933D1 (de) Abrasionsprüfgeräte.
DE58908164D1 (de) Füllelement.
NO881384L (no) Peptider.
FI892357L (fi) Pressad spole.
DE68922166D1 (de) Chiffrierverfahren mit nachträglicher Quellenkodierung.
NO885108L (no) Peptider.
DE68908979D1 (de) Proben-Einspritzvorrichtung.
FI902803A7 (fi) DNA-sekvenssi, joka koodaa a-amylaasi-pullulanaasientsyymiä
FI894069A7 (fi) Sulfonamidoalkyl -cykloalkanfoereningar, foerfarande foer framstaellning daerav samt laekemedel.
FI893450A0 (fi) Modifierade proteiner.
DK324287A (da) Antistof mod koensspecifikt antigen
FI891308A7 (fi) Uudet polypeptidit, joilla on kasvutekijäaktiivisuutta sekä polypeptideitä koodittavat nukleiinihapposekvenssit
FI892254A0 (fi) Anvaendning av a-aminoboronsyraderivat foer stabilisering av peptid- och proteinlaekemedel.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment